DeutschesFachbuch.de : Therapeutic Lipidology

INHALTSVERZEICHNIS | öffnen

Contents
Foreword vii
Preface xi
Acknowledgments xv
Contributors xix
List of Color Plates xxi
1. Lipoprotein Metabolism and Vascular Biology 1
Brian G. Choi, Juan J. Badimon, Pedro R. Moreno, and Valentin Fuster
2. Genetic Disorders of Lipoprotein Metabolism 23
Marina Cuchel, Atif Qasim, and Daniel J. Rader
3. International Guidelines for Dyslipidemia Management 37
Cathleen E. Maki
4. Pathophysiology and Management of Dyslipidemias Associated
with Obesity, Type 2 Diabetes, and Other Insulin-Resistant States 55
Kevin C. Maki
5. C-Reactive Protein and Other Inflammatory Markers
in Cardiovascular Disease 69
Natalie Khuseyinova and Wolfgang Koenig
6. Dietary Prescriptions to Control Dyslipidemias and Coronary Disease Risk 113
Margo A. Denke
7. Pharmacological Therapy for Cardiovascular Disease:
Current and Emerging Therapies 121
Michael H. Davidson
8. Effects of Thiazolidinediones on Serum Lipoproteins 149
Anjli Maroo and W. H. Wilson Tang
9. High-Density Lipoproteins 159
Peter P. Toth
10. Management of Hypertriglyceridemia 201
Reginald Labossiere and Ira J. Goldberg
11. Lowering Low-Density Lipoprotein Cholesterol Levels to Reduce
Atherosclerotic Coronary Heart Disease Risk 221
Harold E. Bays
12. Lipoprotein(a) as an Emerging Risk Factor for Atherothrombosis:
Principles from Bench to Bedside 241
Michael B. Boffa, Santica M. Marcovina, and Marlys L. Koschinsky
13. Familial Hypercholesterolemia and Lipid Apheresis 267
Patrick M. Moriarty, Cheryl A. Gibson, and Klaus Flechsenhar
14. Phytosterolemia: Synthesis, Absorption, Trafficking, and Excretion
of Cholesterol and Noncholesterol Sterols 291
Thomas Dayspring
15. Utilization of Lipoprotein Subfractions 321
William C. Cromwell and James D. Otvos
16. Cardiovascular Disease in Women: The Management of Dyslipidemia 349
Emma A. Meagher
17. Management of Lipids in the Elderly 369
Micah J. Eimer and Neil J. Stone
18. The Clinical Use of Noninvasive Modalities in the Assessment
of Atherosclerosis 389
Atul R. Chugh, Samir N. Patel, Venkataraman Rajaram,
Rachel Neems, Matt Feinstein, Marshall Goldin,
and Steven B. Feinstein
19. Management of Dyslipidemia in Children 409
Stephen R. Daniels
20 The Allied Health Professional's Role in the Management of Dyslipidemia 425
Lynne T. Braun and Joan E. Mathien
21 Development and Management of a Lipid Clinic 441
Carol M. Mason
22. The American Board of Clinical Lipidology Physician Certification Program 477
Nicola A. Sirdevan
Index 481
[weiter lesen]

REGISTER | öffnen

Index
AABCAl deficiency, see Tangier disease
ABCG 5 and ABCG 8 gene, 298-300, 312
ABCL, see American Board of Clinical Lipidology
ABCL physician certification program
- basic requirements for candidates, 478-479
-certifying examination, 479-480
-clinical lipidology and, 478
-training criteria, 479
Accrediation Council for Clinical Lipidology
- (ACCL), 480
Acetyl coenzyme A (CoA), 291
Action to Control Cardiovascular Risk in Diabetes (ACCORD), 360
Acute coronary syndrome (ACS), 12, 70
Acyl cholesterol acyltransferase (ACAT), 6
- Acyl-CoA cholesterol acyltransferase 2 (ACAT 2), 297
- production, 300
Adiponectin, 93, 96
Adult Treatment Panel III (ATP III), 57, 222, 248, 357, 369, 426-427
Age-related macular degeneration (AMD), 282
American Board of Clinical Lipidology, 454-455, 477
American Heart Association (AHA), 37, 350, 443
- cardiovascular risk assessment and, 352-353 8-aminocaproic acid, 242
Angina pectoris (AP), 70
Angiotensin converting enzyme (ACE), 273
Angiotensin-Converting enzyme inhibitors, 52
Angiotensin II receptor blockers, 52
Anglo-Scandinavian Cardiac Outcomes Trial
- (ASCOT), 128
Anglo-Scandinavian Cardiac Outcomes Trial
- (ASCOT)-Lipid-Lowering Arm
- (ASCOT-LLA), 371
Ankle-Brachial Index (ABI), 382, 398-399
Annexin-2 (ANX 2), 296
Antihypertensive and Lipid-Lowering Treatment to
- Prevent Heart Attack Trial (ALLHAT), 372
Antipsychotic medications, 212
ApoA-I on aortic atheromatous plaque, hepatic
- expression of, 167
ApoA-IV expression, in humans, 298
ApoB 48, 297-298
Apolipoprotein(a) [apo(a)], 242, 259-261
-isoform size, cardiovascular disease risk and, 250-251
-statin effect and, 248
- structure and functional implication, 242-246
Apolipoprotein B, 41-42
Apolipoprotein C-II deficiency, 23
Apolipoprotein E (apo-E) polymorphisms, 295
Apolipoprotein E 3-Leiden (E 3 L) transgenic mice, 73
Apolipoproteins, 3-5
- classification, 5
- Apoprotein C-II deficiency, 205
Aspirin therapy, 248
Assessment of Diabetes Control and Evaluation of
- Efficacy of Niaspan Trial (ADVENT), 137
Asymptomatic atherosclerosis, clinicopathologic
- correlation of, 11
Atherogenic dyslipidemia
- drug therapies for, 62
- features of, 57
- lifestyle management for, 61
- lipoprotein and hepatic lipases in, 61
Atherosclerosis, in children, 409-410
Atherosclerosis Risk in Communities (ARIC), 249, 391
Atherothrombosis, 10
- endothelial dysfunction, 12-13
- lipid efflux and plaque rupture, 15
- lipid influx, 13
- phases, 10-13
Atorvastatin, 63, 128
ATP-binding cassette transport Al (ABCAl), 297, 300
Awareness, CVD in women and, 349-350
BBehavioral changes and lifestyle, CVD in women
- and, 357
Bezafibrate infarction prevention, 86
Bile acid (BA), 296
- synthesis, 301
Bile acid binding agents, 417-418
Bile acid séquestrants (BASs), 134, 230, 361-362
- potential adverse affects and drug interactions with, 235
Blood viscosity, LDL apheresis and, 279-280
Body mass index (BMI), 461
Brachial artery reactivity testing, 399-400 "Break-even planning, " 448
Bypass Angioplasty Revascularization Investigation 2 D (BARI 2 D), 155
CCanadian Consensus Conference of Cholesterol
- (CCCC), 37
Cardiac Magnetic Resonance Imaging (CMRI), 397-398
Cardiovascular disease, 37, 441
- lipoproteins and, 354-356
- Lp(a) and, 248-250
- risk, APO(a) isoform size and, 250-251
- risk of developing, 50-51
Cardiovascular Health Study (CHS), 74, 391
Cardiovascular response and lipid changes, fibrate,
- statin, niacin and, 175-181
Cardiovascular risk assessment
- AHA and, 352-353
- lipoproteins and CVD, 354-356
Carotid Artery Intima-Media Thickness (c-IMT), 390
- extra-carotid sites, 394
- measurement, 183, 381-382
- method and technology, variations in, 392-393
- observational and clinical studies, 391-392
- risk group identification, 392
Caveolin-1 (CAV 1), 296
CD 40/CD 40 L signaling pathway, 89
c 7 E 3
Anti-Platelet Therapy in Unstable REfractory
- angina (CAPTURE), 88
Cell adhesion molecules (CAMs), 72
Cerebral vascular disease (CVD), LDL apheresis and, 283-284
CHD, LDL-C lowering and, 221
cholesterol absorption inhibitor, statin and, 234-238
- ezetimibe, 224-230
- lipid-altering drugs and, 222
- pathophysiology of, 222
- resins and polymers, 230-234
- statins, 224
- treatment goals, 222-224
Cholestech LDX analyzer, 464
Cholesterol, 1, 292-293;
see also Sterols absorption
- absorption inhibitors, 234, 362-363, 419
- absorption, statins and, 307-309
- LDLr deficiency and, 297
Cholesterol abnormalities, in children, 410-411
- individual approach
- bile acid binding agents, 417-418
cholesterol absorption inhibitors, 419
diet therapy, 415-417 fibric acid derivatives, 419
HMG-CoA reductase inhibitors, 418 pharmacologic intervention, 417 screening, 413-414 ...
- population approach, 411-413
Cholesterol 7 a-hydroxylase (CYP 7 A 1), 300
Cholesterol and Recurrent Events (CARE) trial, 79
Cholesterol ester (CE), 1-2, 296-300
Cholesterol ester transfer protein (CETP), 4, 9, 300
- deficiency, 32
Cholesterol-lowering therapy, 121
Cholesterol Treatment Trialists' Collaborators, 373
Cholesteryl ester transfer protein (CETP), 59, 142-143, 161
Cholestyramine, 114
Chylomicronemia, 204
Chylomicrons, 6
Clinical psychologist's role, dyslipidemia management
- and, 436-437
Coagulation and fibrinolysis cascade., 82
Collaborative Atorvastatin Diabetes Study
- (CARDS), 128
Combination therapy, dyslipidemia treatment and, 362-363
Combined hyperlipidemia, dietary therapy, 118
Compensatory hyperinsulinemia, 58
Concomitant TZD and statin therapy, 154
Coronary angiography, 84-85
Coronary artery calcification (CAC), and elderly, 381
Coronary artery disease (CAD), 269, 276
- LDL apheresis and, 281
Coronary Computed Tomography (CT) Imaging
- EBCT, 394-396
- MDCT, 396-397
Coronary Flow Reserve (CFR), noninvasive assessment
- of, 400-402
Coronary heart disease (CHD), 69, 221, 441
- and LDL apheresis, 275
- LDL-C and, 425
- Lp(a) level, as risk factor for, 248-249
- morbidity and mortality associated with, 121
- NCEP guidelines and, 242
Corticosteroids, 211
C-reactive protein (CRP), 43, 70-75, 276
- in atherogenesis, 73
- and elderly, 378-379
- transgenic mice, 73
CVD, see Cardiovascular disease CVD, in women
cardiovascular risk assessment, 352-356
identification, 349-352
combination therapy, for dyslipidemia, 362-363
- drug therapy, 358-362
- lifestyle and behavioral changes, 357
- treatment, 356-357
Cyclosporine, 130
CYP 3 A 4 pathway, 129
Cytochrome CYP 2 C 8-metabolized drugs, 140
Cytochrome P 450 (CYP) 3 A 4 enzyme system, 231
DDanazol and tibolone, Lp(a) levels reduction and, 247-248
Density Gradient Ultracentrifugation (DGU), 328-329
Dextran sulfate cellulose adsorption (DSA), 272-273
Diabetes, CVD in women and, 351-352
Diabetes Mellitus, 51-52
- Type 2, 56-57
Diabetes Outcome Progression Trial (ADPOT), 155
Diabetic dyslipidemia, 65
Diabetic nephropathy, LDL apheresis and, 280-281
Diacylglycerol acyltransferase (DGAT), 64
Dietary Intervention Study in Children (DISC), 415
Dietary prescriptions, dyslipidemia and, 113
Dietary therapy, 113
Diet, evolving role of
- early statin years, LDL lowering (1987-1994), 114
- pre-statin cholesterol lowering (1960-1987), 114
- statin Trials, LDL Lowering, (1994-2004), 115
[weiter lesen]